Active clinical trials of the Pediatric Early Clinical Trials East Network.

Please find here an overview of our current clincical trial portfolio.

If you are interested in participating in a specific study,

Please do not hesitate to contact us!

Leukemias
Lymphomas
Solid Tumors
ZNS Tumors
Other diseases

Active clinical trials of the Research Network

On this page you will find an overview of our currently active studies. If you are interested in participating in a specific study, please email the contact person at the respective clinics. You will find the contact information via the respective link to the website of the respective study locations.

Please do not hesitate to contact us!

Leukämien
Lymphome
Solid Tumors
ZNS Tumors
Other diseases

Leukemias


Investigational drug: Inotuzumab

Indication: CD22+ relapsed/refractory BCP-ALL

Phase: II

Protocol Nr.: ITTC-059 / NTR5736

EudraCT/NCT-Nr.: EudraCT2016-000227-71

Trial location: Berlin, Charité

Investigational drug: Midostaurin

Indication: FLT3pos AML

Phase: II

Protocol Nr.: CPKC412A2218

EudraCT/NCT-Nr.: EudraCT2017-004830-28

Trial location: Berlin, Charité

Prüfpräparat: VyClo (CPX-351 + Clofarabine)

Indikation: Relapsed or refractory pediatric AML

Phase: Ib

Prüfplan-Nr.: ITCC-092-VyClo

EudraCT/NCT-Nr.: EudraCT2020-000142-34

Studienstandort: Berlin, Charité

Investigational drug: Cellgene JCAR

Indication: B-ALL + B-NHL

Phase: I/II

Protocol Nr.: JCAR017-BCM-004

EudraCT/NCT-Nr.: EudraCT2018-001246-34

Trial location: Berlin, Charité

Investigational drug: MB-CART19.1

Indication: B-ALL REZ

Phase: II/III

Protocol Nr.: M-2017-322

EudraCT/NCT-Nr.: EudraCT2017‐002848‐32

Trial location: Berlin, Charité

Prüfpräparat: Inotuzumab vs. SOC Induction R3 (Pfizer)

Indikation: ALL

Phase: III

Prüfplan-Nr.: Inotuzumab vers. R3

EudraCT/NCT-Nr.: EudraCT2022-000186-40

Studienstandort: Berlin, Charité

Lymphomas


Investigational drug: Brigatinib

Indication: ALK+ ALCL, Solid Tumors, IMT

Phase: I/II

Protocol Nr.: ITCC-098 Briga Ped

EudraCT/NCT-Nr.: EudraCT2021-002713-34

Trial location: Berlin, Charité

Prüfpräparat: Crizotinib +/- CTx Kombination

Indikation: Malignancies carrying a genetic alteration of ALK, MET or ROS1

Phase: Ib

Prüfplan-Nr.: ITCC-053 CRISP

EudraCT/NCT-Nr.: EudraCT2015‐005437‐53

Studienstandort: Berlin, Charité

Investigational drug: Cellgene JCAR

Indication: B-ALL + B-NHL

Phase: I/II

Protocol Nr.: JCAR017-BCM-004

EudraCT/NCT-Nr.: EudraCT2018-001246-34

Trial location: Berlin, Charité

Investigational drug: Pembrolizumab

Indication: Hodgkin Lymphoma

Phase: II

Protocol Nr.: Keynote 667

EudraCT/NCT-Nr.: EudraCT2017-001123-53

Trial location: Berlin, Charité

Solid Tumors


Investigational drug: Abemaciclib

Indication: Relapsed/Refractory Solid Tumors

Phase: I/II

Protocol Nr.: JP04

EudraCT/NCT-Nr.: NCT05440786

Trial location: Berlin, Charité

Investigational drug: Brigatinib

Indication: ALK+ ALCL, Solid Tumors, IMT

Phase: I/II

Protocol Nr.: ITCC-098 Briga Ped

EudraCT/NCT-Nr.: EudraCT2021-002713-34

Trial location: Berlin, Charité

Prüfpräparat: Dabrafenib + Trametinib (CDRB436G2201 Rollover)

Indikation: V600 Mutationen

Phase: IV

Prüfplan-Nr.: CDRB436G2401

EudraCT/NCT-Nr.: EudraCT2018-004459-19

Studienstandort: Berlin, Charité

Investigational drug: Larotrectinib

Indication: Solid Tumors

Phase: I/II

Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)

EudraCT/NCT-Nr.: EudraCT2016-003498-16

Trial location: Berlin, Charité

Prüfpräparat: Niraparib (PARP inhbitor) + Dostarlimab (PD-1 inhibitor)

Indikation:

Phase: I/II

Prüfplan-Nr.: GlaxoSmithKline

EudraCT/NCT-Nr.: on hold

Studienstandort: Berlin, Charité

Investigational drug: Abemaciclib (Solide Tumore)

Indication: Relapsed/Refractory Solid Tumors

Phase: Ib

Protocol Nr.: I3Y-MC-JPCS

EudraCT/NCT-Nr.: EudraCT2019-002931-27

Trial location: Berlin, Charité

Prüfpräparat: Crizotinib +/- CTx Kombination

Indikation: Malignancies carrying a genetic alteration of ALK, MET or ROS1

Phase: Ib

Prüfplan-Nr.: ITCC-053 CRISP

EudraCT/NCT-Nr.: EudraCT2015‐005437‐53

Studienstandort: Berlin, Charité

Investigational drugs: DAY101 FIREFLY-1

Indication: Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

Phase: I/II

Protocol Nr.: FireFly DAY 101

EudraCT/NCT-Nr.: EudraCT2020-003657-30

Trial location: Berlin, Charité

Investigational drug: Nivolumab + Entinostat

Indication: Refractory high risk malignoma

Phase: I/II

Protocol Nr.: INFORM2 NivEnt

EudraCT/NCT-Nr.: EudraCT2018-000127-14

Trial location: Berlin, Charité

ZNS Tumors


Investigational drugs: DAY101 FIREFLY-1

Indication: Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

Phase: I/II

Protocol Nr.: FireFly DAY 101

EudraCT/NCT-Nr.: EudraCT2020-003657-30

Trial location: Berlin, Charité

Investigational drug: Larotrectinib

Indication: Solid Tumors

Phase: I/II

Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)

EudraCT/NCT-Nr.: EudraCT2016-003498-16

Trial location: Berlin, Charité

Prüfpräparat: DAY101 Monotherapy vs. SOC Chemotherapy

Indikation: pan RAFi

Phase: III

Prüfplan-Nr.: FireFly DAY 102

EudraCT/NCT-Nr.: EudraCT2022-001363-27

Studienstandort: Berlin, Charité

Investigational drug: Selumetinib

Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)

Phase: I/II

Protocol Nr.: SPRINKLE D1346C00004

EudraCT/NCT-Nr.: EudraCT2020-005608-20

Trial location: Berlin, Charité

Other deseases


Investigational drug: CDZ173/Leniolisib

Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)

Phase: II/III

Protocol Nr.: CCDZ173X2201

EudraCT/NCT-Nr.: EudraCT2016-000468-41

Trial location: Dresden

Prüfpräparat: HSZT multispezifische T-Zellen

Indikation: Chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation

Phase: III

Prüfplan-Nr.: TRACE

EudraCT/NCT-Nr.: EudraCT2018-000853-29

Studienstandort: Berlin, Charité

Investigational drug: Crizanlizumab

Indication: Sickel cell disease

Phase: II

Protocol Nr.: CSEG 101B2201

EudraCT/NCT-Nr.: EudraCT2017-001747-12

Trial location: Berlin, Charité